TY - JOUR
T1 - Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms
AU - Sawai, Y.
AU - Yamao, K.
AU - Bhatia, V.
AU - Chiba, T.
AU - Mizuno, N.
AU - Sawaki, A.
AU - Takahashi, K.
AU - Tajika, M.
AU - Shimizu, Y.
AU - Yatabe, Y.
AU - Yanagisawa, A.
PY - 2010
Y1 - 2010
N2 - Background and study aims: Side-branch intraductal papillary mucinous neoplasms (SB-IPMNs), and associated synchronous and metachronous pancreatic cancers are increasingly detected as imaging modalities become more sensitive. We investigated the natural history of SB-IPMN, and the incidence and characteristics of pancreatic cancers among patients undergoing long-term follow-up. Patients and methods: We reviewed the clinical, imaging, and pathological features in 103 patients, diagnosed at the Aichi Cancer Center between September 1988 and September 2006 as having SB-IPMN, and conservatively followed up for 2 years (median 59 months) based on an endoscopic ultrasonography (EUS) database. Results: 74 (71.8%) patients had nonprogressive lesions. Overall, six patients (5.8%) developed pancreatic cancers during follow-up, with intraductal papillary mucinous (IPM) carcinoma in four, and ductal carcinoma of pancreas that was not IPMN in two patients. Of the six pancreatic cancers, five were diagnosed at a resectable stage. The 5-year and 10-year actuarial rates of development of pancreatic cancer were 2.4% and 20.0%, respectively. Although, at the last follow-up, cyst size, main pancreatic duct (MPD) diameter, mural nodule size, and frequency of metachronous and/or synchronous cancers of other organs were significantly higher in patients who developed IPM carcinoma, resected SB-IPMNs without mural nodules and dilated MPDs had no IPM carcinomas. Conclusions: The frequency of pancreatic cancers is high on long-term follow-up of SB-IPMN. Although conservative management is appropriate for selected patients, regular and long-term imaging, especially by EUS is essential, even if SB-IPMN remains unchanged for 2 years. Presence of mural nodule and dilated MPD seem to be more appropriate indicators for resection than cyst size alone for SB-IPMNs.
AB - Background and study aims: Side-branch intraductal papillary mucinous neoplasms (SB-IPMNs), and associated synchronous and metachronous pancreatic cancers are increasingly detected as imaging modalities become more sensitive. We investigated the natural history of SB-IPMN, and the incidence and characteristics of pancreatic cancers among patients undergoing long-term follow-up. Patients and methods: We reviewed the clinical, imaging, and pathological features in 103 patients, diagnosed at the Aichi Cancer Center between September 1988 and September 2006 as having SB-IPMN, and conservatively followed up for 2 years (median 59 months) based on an endoscopic ultrasonography (EUS) database. Results: 74 (71.8%) patients had nonprogressive lesions. Overall, six patients (5.8%) developed pancreatic cancers during follow-up, with intraductal papillary mucinous (IPM) carcinoma in four, and ductal carcinoma of pancreas that was not IPMN in two patients. Of the six pancreatic cancers, five were diagnosed at a resectable stage. The 5-year and 10-year actuarial rates of development of pancreatic cancer were 2.4% and 20.0%, respectively. Although, at the last follow-up, cyst size, main pancreatic duct (MPD) diameter, mural nodule size, and frequency of metachronous and/or synchronous cancers of other organs were significantly higher in patients who developed IPM carcinoma, resected SB-IPMNs without mural nodules and dilated MPDs had no IPM carcinomas. Conclusions: The frequency of pancreatic cancers is high on long-term follow-up of SB-IPMN. Although conservative management is appropriate for selected patients, regular and long-term imaging, especially by EUS is essential, even if SB-IPMN remains unchanged for 2 years. Presence of mural nodule and dilated MPD seem to be more appropriate indicators for resection than cyst size alone for SB-IPMNs.
UR - http://www.scopus.com/inward/record.url?scp=78649496663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649496663&partnerID=8YFLogxK
U2 - 10.1055/s-0030-1255971
DO - 10.1055/s-0030-1255971
M3 - Article
C2 - 21120776
AN - SCOPUS:78649496663
SN - 0013-726X
VL - 42
SP - 1077
EP - 1084
JO - Endoscopy
JF - Endoscopy
IS - 12
ER -